Sapelin B
Sapelin B is a naturally occurring tirucallane-type triterpenoid that exhibits in vivo antitumor activity in a mouse model of P-388 lymphocytic leukemia. Sapelin B can be used in leukemia-related research.
For research use only. We do not sell to patients.
- CAS No.: 26790-94-3
- Formula: C30H50O4
- Molecular Weight:474.72
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
10 μM
Compound: 26
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 27494664] |
| A549 | IC50 |
>10 μM
Compound: 26
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 27494664] |
| MCF7 | IC50 |
>10 μM
Compound: 26
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 27494664] |
| MCF7 | IC50 |
10 μM
Compound: 26
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 27494664] |
| MKN-28 | IC50 |
>10 μM
Compound: 26
|
Cytotoxicity against human MKN28 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human MKN28 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 27494664] |
| MKN-28 | IC50 |
10 μM
Compound: 26
|
Cytotoxicity against human MKN28 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human MKN28 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 27494664] |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 26790-94-3
-
Molecular Weight 474.72
-
Formula C30H50O4
-
SMILES
CC1([C@@H](CC[C@@]2([C@]3(CC[C@]4([C@](CC[C@@]4(C3=CC[C@@]12[H])C)([H])[C@@]5([H])COC(C)(C)[C@@H](O)[C@H](O)C5)C)[H])C)O)C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)